❗Help close the gap: We still need to raise $40,000 by the end of March. Donate now

The benefits of developing an Ebola vaccine

Jim Burress Sep 2, 2014
HTML EMBED:
COPY

The benefits of developing an Ebola vaccine

Jim Burress Sep 2, 2014
HTML EMBED:
COPY

This week, the National Institutes of Health begins testing an Ebola vaccine in humans. Given the need to quickly stem the deadly outbreak in West Africa, global health officials hope to push a vaccine to market.

While there’s currently a market for an Ebola vaccine, it’s small, and Ebola isn’t a disease that keeps popping up year-after-year. 

“It’s not all about economics,” says Dr. Carlos Del Rio, chair of the Department of Global Health at Emory University. He says developing the vaccine is also about building good PR for a company. “There’s a value to that publicity, right?”

Right, says Kenneth Kaitin, director of the Center for Drug Development at Tufts University. But Kaitin says there is also the potential for a huge payoff, especially for smaller companies. 

Think of it as a pharmaceutical version of “Cap and Trade.”

“A program that the FDA put in place several years ago gives a priority review voucher to any company developing a product for a neglected or tropical disease,” says Kaitin.

Ebola is a perfect exampleThat pharma company can sell the voucher to another drug maker. The “golden ticket” gets the purchaser a fast track to federal regulators for any other drug in its portfolio.

One voucher recently sold for more than $67 million.  

There’s a lot happening in the world.  Through it all, Marketplace is here for you. 

You rely on Marketplace to break down the world’s events and tell you how it affects you in a fact-based, approachable way. We rely on your financial support to keep making that possible. 

Your donation today powers the independent journalism that you rely on. For just $5/month, you can help sustain Marketplace so we can keep reporting on the things that matter to you.